EMAIL
PRINT
2 COMMENTSShare and save this post:
Also in DrugReporter
Marijuana Could Be a Gusher of Cash If We Treated It Like a Crop, Not a Crime
Steven Wishnia
Whether It's Sex or Drugs, Abstinence-Only Education Simply Doesn't Work
Marsha Rosenbaum, Jennifer Kern
Lunatic Drug Warriors Still Ignore Powerful Pot Science
Rob Kampia
Obama's Biden Pick Signals 'More of the Same' Stupid Drug Policies
Paul Armentano
New Drug Survey Demolishes Drug Czar's Claims
Bruce Mirken
It might sound far-fetched, but just a decade ago it seemed unlikely that the prohibited and mildly hallucinogenic drug cannabis would become a mainstream pain-killing medicine.
But it is happening: Cannabis pain-killing pills and sprays are being developed to help people with multiple sclerosis, cancer and Aids.
Now some scientists and psychotherapists think more powerful psychoactive drugs like psilocybin, found in 'magic mushrooms', could have a future as medicinal agents for a number of conditions.
In the US, the Food and Drug Administration (FDA) has approved, but not funded, a pilot study aiming to see if the euphoria and insight of a mild psychedelic 'trip' can ease the physical and emotional pain experienced by thousands of terminal cancer patients each year.
Charles Grob, Professor of Psychiatry and Paediatrics at the Harbor-UCLA Medical Centre, California, and lead scientist on the cancer-psilocybin trial, said: "There is great potential. A significant patient population may gain benefits from these treatments."
Professor Grob will be one of the first scientists in 25 years to administer psilocybin to a person in a therapeutic setting.
He wants to see if people's lives can be improved if psychoactive drugs are used under carefully controlled conditions.
Past success
In the past it seemed to work: in the 60s, cancer sufferers reported less anxiety, a reduced fear of death, better moods, and surprisingly, even less pain in the weeks after treatment with LSD, which is similar in structure and effect to psilocybin.
So, what will happen during a 21st century psychedelic therapeutic session?
The subjects will lie down wearing an eye mask to screen out distractions and headphones pumping in gentle music to fully immerse them in their journey.
"We are going to let the patients guide their own experience by reacting only to their needs," said Professor Grob.
"We are there to hold their hands and talk if they feel the need, but we will not overtly attempt to take it in any spiritual or religious direction. It is up to them."
The rationale says it is better to let the drug gently lift the veil, divorce the association between mind and body and let the patient enjoy the full-on experience as they wish, than interfere in a way that may be incompatible with the patient's psyche.
UK perspective
Could this ever cross the water? In the 50s, 60s and 70s, Britain and many European countries were active centres of psychoactive drug research.
Dr Kate Law, of the charity Cancer Research UK, said: "With full, informed consent, we have no problem with it in principle.
"These patients are adults and people make their own choices. It is right that we look at these chemicals with the same stringent standards as we do for other drugs.
"People shy away from the fact that other powerful drugs like heroin are used when caring for cancer patients, many of which have side-effects of their own."
See more stories tagged with: lsd, psilocybin
No comments:
Post a Comment